Swedish biotech company Cantargia recently presented its 2017 Q2 results and it looks like they are ready for their next step, taking them from preclinical to clinical stage. One of the company’s most recent achievements, after the end of Q2, was the patient recruitment to its CANFOUR study. ThAlready a subscriber Login You have read … Continue reading Business in focus: Cantargia